Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9713054 | 0.88 | SMN1; SMN2 (0.67) | HDAC8HDAC6SMN1; SMN2POLBMEN1 | |
| SCHEMBL1753828 | 0.86 | L3MBTL1 (0.71) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL10605827 | 0.85 | HDAC8 (0.65) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL842634 | 0.83 | SMN1; SMN2 (0.81) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL9492626 | 0.82 | NPC1 (0.68) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL1285808 | 0.82 | NPC1 (0.63) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL5857587 | 0.82 | HDAC8 (0.61) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL842631 | 0.82 | NPC1 (0.68) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL29417854 | 0.82 | NPC1 (0.63) | HDAC8HDAC6NPC1RAB9AATM | |
| SCHEMBL10085277 | 0.82 | SMN1; SMN2 (0.73) | HDAC8HDAC6NPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3955736-A1 | MULTIPURPOSE PROTECTANT COMPOSITIONS AND METHODS | Howard, Jr., James Joseph (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2020214165-A1 | MULTIPURPOSE PROTECTANT COMPOSITIONS AND METHODS | HOWARD JAMES JOSEPH JR (US) | 2020-10-22 | — | — | WO | claimed |
| EP-2845595-A1 | Orally administered corticosteriod compositions | Aptalis Pharmatech, Inc. (US) | 2015-03-11 | — | — | EP | claimed |
| EP-2482822-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | Aptalis Pharmatech, Inc. (US) | 2012-08-08 | — | — | EP | claimed |
| WO-2011041509-A1 | ORALLY ADMINISTERED CORTICOSTEROID COMPOSITIONS | EURAND, INC. (US) | 2011-04-07 | — | — | WO | claimed |
| CN-118044519-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-110072842-B | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 科迪华农业科技有限责任公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-111936503-B | Oxazine monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230149405-A1 | TOPICAL USE OF ERLOTINIB FOR TREATING KERATODERMAS IN CHILDREN | LABORATOIRES C.T.R.S. (FR) | 2023-05-18 | — | — | US | disclosed |
| CN-115803007-A | Topical application of erlotinib for treating child keratosis | C.T.R.S.实验室公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-3947514-A | ADIPIC ACID CATALYST | SHOWA DENKO K.K. (JA) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | HDAC8 413/4885HDAC6 121/4885NPC1 128/4885 |
| US-20230149405-A1 | TOPICAL USE OF ERLOTINIB FOR TREATING KERATODERMAS IN CHILDREN | PRKDC, PIK3C3, PRKACB | HDAC8 3792/4885HDAC6 4385/4885NPC1 4425/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | HDAC8 922/4885HDAC6 212/4885NPC1 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.